Co-Diagnostics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
CODX$0.29-9.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Convertible Preferred Stock · Common Stock · Treasury · Additional Paid-in · Accumulated Other Comprehensive · Accumulated Earnings · Total Stockholders’ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Stock · Capital · Income · (Deficit) · Equity | |||||||||||
| Balance as of December 31, 2025 | - | - | 2,256,654 | 67,700 | (15,575,795) | 116,510,298 | - | (80,373,539) | 20,628,664 | ||
| Issuance of common stock related to at-the-market offering, net of offering costs | - | - | 1,507,434 | 1,507 | - | 4,333,163 | - | - | 4,334,670 | ||
| Stock-based compensation | - | - | - | - | - | 219,114 | - | - | 219,114 | ||
| Net loss | - | - | - | - | - | - | - | (9,140,038) | (9,140,038) | ||
| Balance as of March 31, 2026 | - | - | 3,764,088 | 69,207 | (15,575,795) | 121,062,575 | - | (89,513,577) | 16,042,410 | ||
| Stock-based compensation | - | - | 29,045 | 29 | - | 213,723 | - | - | 213,752 | ||
| Issuance of common stock related to private placement transaction and warrant exercises, net of offering costs | - | - | 1,247,447 | 1,248 | - | 2,738,725 | - | - | 2,739,973 | ||
| Net loss | - | - | - | - | - | - | - | (6,283,786) | (6,283,786) | ||
| Balance as of June 30, 2026 | - | $ | - | 5,040,580 | $70,484 | $(15,575,795) | $124,015,023 | $ | - | $(95,797,363) | $12,712,349 |
| Convertible Preferred Stock · Common Stock · Treasury · Additional Paid-in · Accumulated Other Comprehensive · Accumulated Earnings · Total Stockholders’ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Stock · Capital · Income · (Deficit) · Equity | ||||||||||
| Balance as of December 31, 2024 | - | $ | - | 1,263,408 | $37,902 | $(15,575,795) | $102,472,210 | $418,443 | $(33,477,603) | $53,875,157 |
| Issuance of common stock related to at-the-market offering, net of offering costs | - | - | 17,303 | 519 | - | 354,227 | - | - | 354,746 | |
| Stock-based compensation | - | - | - | - | - | 875,228 | - | - | 875,228 | |
| Other comprehensive loss, net of tax | - | - | - | - | - | - | (87,790) | - | (87,790) | |
| Net loss | - | - | - | - | - | - | - | (7,533,271) | (7,533,271) | |
| Balance as of March 31, 2025 | - | - | 1,280,711 | 38,421 | (15,575,795) | 103,701,665 | 330,653 | (41,010,874) | 47,484,070 | |
| Issuance of common stock related to at-the-market offering, net of offering costs | - | - | 45,845 | 1,375 | - | 427,625 | - | - | 429,000 | |
| Stock-based compensation | - | - | 24,482 | 735 | - | 579,530 | - | - | 580,265 | |
| Issuance of common stock related to financial advisory services | - | - | 16,667 | 500 | - | 134,500 | - | - | 135,000 | |
| Other comprehensive loss, net of tax | - | - | - | - | - | - | (196,585) | - | (196,585) | |
| Net loss | - | - | - | - | - | - | - | (7,730,117) | (7,730,117) | |
| Balance as of June 30, 2025 | - | - | 1,367,705 | 41,031 | (15,575,795) | 104,843,320 | 134,068 | (48,740,991) | 40,701,633 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.